Mariko Nakafuji

Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom.

Mizuho Securities Co., Ltd. (Broker) (Mizuho Securities-Broker) is the brokerage division of Mizuho Securities Co. Ltd., ultimately owned by Mizuho Financial Group, Inc. (TYO: 8411; NYSE: MFG) in Japan. The firm was originally founded in 1917 and is headquartered in Tokyo with a network of offices throughout Japan as well as overseas representation through Mizuho entities or strategic partners (in Great Britain, Switzerland, the US, Hong Kong, Mainland China, South Korea, Singapore and India). Mizuho Securities-Broker provides enhanced equity and fixed income execution services for their clients who includes private individuals in Japan, domestic and foreign institutions, non-financial companies, financial institutions and public corporations in the securities and investment banking fields.

Jitsubo Co., Ltd. researches, develops, and produces peptides. It operates as a peptide development company that provides solutions to patients using their proprietary technologies for manufacturing and engineering peptides. The firm specializes in peptide synthesis, which enables users to modify amino acid sequence for the creation of physical, chemical, and pharmacological properties. It also engages in development of peptide pharmaceuticals, licensing regarding active ingredient manufacturing technology for peptides, and peptide drug discovery research. The company was founded by Yusuke Kohno and Kazuhiro Chiba in 2000 and is headquartered in Tokyo, Japan.